BFRG Stock Overview
Through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Bullfrog AI Holdings, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.90 |
52 Week High | US$8.35 |
52 Week Low | US$2.36 |
Beta | 0 |
1 Month Change | -0.68% |
3 Month Change | -33.94% |
1 Year Change | -49.12% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -39.08% |
Recent News & Updates
Recent updates
Shareholder Returns
BFRG | US Healthcare Services | US Market | |
---|---|---|---|
7D | -2.7% | 1.8% | 1.6% |
1Y | -49.1% | -2.5% | 26.1% |
Return vs Industry: BFRG underperformed the US Healthcare Services industry which returned -3% over the past year.
Return vs Market: BFRG underperformed the US Market which returned 26.8% over the past year.
Price Volatility
BFRG volatility | |
---|---|
BFRG Average Weekly Movement | 11.6% |
Healthcare Services Industry Average Movement | 10.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.3% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: BFRG's share price has been volatile over the past 3 months.
Volatility Over Time: BFRG's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | 6 | Vin Singh | www.bullfrogai.com |
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease.
Bullfrog AI Holdings, Inc. Fundamentals Summary
BFRG fundamental statistics | |
---|---|
Market cap | US$23.94m |
Earnings (TTM) | -US$5.92m |
Revenue (TTM) | US$65.00k |
350.3x
P/S Ratio-3.8x
P/E RatioIs BFRG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BFRG income statement (TTM) | |
---|---|
Revenue | US$65.00k |
Cost of Revenue | US$5.20k |
Gross Profit | US$59.80k |
Other Expenses | US$5.98m |
Earnings | -US$5.92m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.75 |
Gross Margin | 92.00% |
Net Profit Margin | -9,103.60% |
Debt/Equity Ratio | 7.5% |
How did BFRG perform over the long term?
See historical performance and comparison